Publication

Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Publications related to Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma | EPFL Graph Search

Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma

Graph Chatbot

Chat with Graph Search

Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies

Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Cell-free method for the quantitative measurement of virus neutralizing antibodies

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Specchio-COVID19 cohort study: a longitudinal follow-up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland

Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus

A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies

Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model

Cell-free method for the quantitative measurement of virus neutralizing antibodies

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

Specchio-COVID19 cohort study: a longitudinal follow-up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys